Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0361120040180020134
Korean Journal of Transplantation
2004 Volume.18 No. 2 p.134 ~ p.139
Analysis of Pretransplant ELISA-Panel Reactive Antibody in Kidney Transplant Patients
¿ÀÀºÁö/Oh EJ
¹Ú¿¬ÁØ/À̱³¿µ/ÃÖ¹ü¼ø/¾çö¿ì/±è¿ë¼ö/¹æº´±â/°í¿ëº¹/°­Ã¢¼®/Park YJ/Lee KY/Choi BS/Yang CW/Kim YS/Bang BK/Koh YB/Kang CS
Abstract
Purpose: HLA antibodies have been shown to be associated with graft loss of organ transplants in prior studies. This study was designed to analyze the results of ELISA- panel reactive antibody (ELISA-PRA) in kidney transplant patients and the impact of this test on the clinical outcome.

Methods: We have investigated ELISA-PRA results from 110 living donor renal transplant patients from Nov. 2001 to Apr. 2004.

Results: ELISA-PRA positivity was found in 22 (20%) patients and was higher in the female patients than male (P<0.05). Pretransplant transfusion, pregnancy or transplantation history was not significantly correlated with ELISA- PRA result. ELISA-PRA ( )patients had more rejection episodes of 41% (n=9) (P=0.0005) and graft failures of 18% (n=4) (P=0.028) than ELISA-PRA ( ), which had 8% (n=7) and 3% (n=3), respectively. Patients group with a result of ELISA-PRA/flowcytometric crossmatch (FCXM) ( / ) or ( / ) had worse clinical outcome than ELISA- PRA/FCXM ( / ). ELISA-PRA/FCXM ( / ) correlated with higher incidence of allograft rejection than ELIS- PRA/FCXM ( / ) or ( / ).

Conclusion: These results suggest that in conjunction with FCXM results, pretransplant ELISA-PRA test is useful predictor of clinical outcome in renal transplant recipients.
KEYWORD
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø